Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

Abstract

Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48•7%] women; median age 51•0 years [IQR 40•7-59•7]). 199 415 individuals were included in the derivation cohort (91 786 [48•4%] women) and 199 431 (92 269 [49•1%] women) in the validation cohort. During a maximum follow-up of 43•6 years (median 13•5 years, IQR 7•0-20•1), 54 542 cardiovascular endpoints occurred. Incidence curve analyses showed progressively higher 30-year cardiovascular disease eventrates for increasing non-HDL cholesterol categories (from 7•7% for non-HDL cholesterol <2•6 mmol/L to 33•7% for ≥5•7 mmol/L in women and from 12•8% to 43•6% in men; p<0•0001). Multivariable adjusted Cox models with non-HDL cholesterol lower than 2•6 mmol/L as reference showed an increase in the association between non-HDL cholesterol concentration and cardiovascular disease for both sexes (from hazard ratio 1•1, 95% CI 1•0-1•3 for non-HDL cholesterol 2•6 to <3•7 mmol/L to 1•9, 1•6-2•2 for ≥5•7 mmol/L in women and from 1•1, 1•0-1•3 to 2•3, 2•0-2•5 in men). The derived tool allowed the estimation of cardiovascular disease event probabilities specific for non-HDL cholesterol with high comparability between the derivation and validation cohorts as reflected by smooth calibration curves analyses and a root mean square error lower than 1% for the estimated probabilities of cardiovascular disease. A 50% reduction of non-HDL cholesterol concentrations was associated with reduced risk of...

Sex-Related Differences of the Effect of Lipoproteins and Apolipoproteins on 10-Year Cardiovascular Disease Risk; Insights from the ATTICA Study (2002–2012)

“…Here, we showed that the lowest hazard for CVD was found in women and men with the lowest non-HDL-C concentrations. This is in accordance with outcomes revealed from the Multinational Cardiovascular Risk Consortium, where a continuous and linear increase for higher non-HDL-C concentrations was observed [15]. Additionally, several works suggest that the non-HDL-C/HDL-C ratio is superior to traditional lipid markers in estimating arterial stiffness and atherosclerosis, with this association being more evident in the case of women [24,25].…”

“…Nevertheless, no robust conclusions exist, while their clinical use is often overlooked [4]. On the other hand, the hitherto literature related with these alternative lipid biomarkers lacks in the aforementioned need for a sex-specific orientation [13][14][15].…”

Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis

“…The inclusion of apolipoprotein-B-related measures leads to modest incremental increases in predictive performance [20]. Pooled data from over 500,000 individuals across 44 cohorts identified non-highdensity lipoprotein (non-HDL) cholesterol (an approximation to the number of apolipoprotein-B-containing particles) to strongly associate with risk of incident cardiovascular disease [21]. When the concentrations of apolipoprotein B and LDL cholesterol are discordant in individuals, apolipoprotein B has a stronger association with risk of cardiovascular disease (CVD) than LDL cholesterol [22].…”

Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer

“…Altered lipid metabolism, which is relevant to hematopoietic activity and the risk of several immunological diseases, including cardiovascular disease, obesity and cancer, has recently received increasing attention [72,73]. Fatty acids provide an efficient way to generate energy via fatty acid oxidation (FAO, also known as β-oxidation), through which acetyl-CoA is produced to participate in the tricarboxylic acid (TCA) cycle, oxidative phosphorylation (OXPHOS) and fatty acid synthesis to meet the substantial cellular energy needs in the TME [74,75].…”